BZBarbara Zalewska

Barbara Zalewska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Barbara Zalewska has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phytonutrients in Diseases of Affluence: Advances, Mechanisms, and Therapeutic Perspectives

    by Katarzyna Zalewska, Barbara Zalewska, Przemysław Zalewski

    Diseases of affluence, including obesity, type 2 diabetes mellitus, cardiovascular diseases, metabolic dysfunction-associated steatotic liver disease (MASLD), inflammatory bowel diseases, and selected cancers, represent some of the most significant public health challenges worldwide

  • Top Cited Papers
    Open Access

    Chlorogenic Acid’s Role in Metabolic Health: Mechanisms and Therapeutic Potential

    by Katarzyna Zalewska, Maciej Kulawik, Julia Gierszewska, Zofia Gramala, Oliwia Kalus, Michał Karpiński, Joanna Maćkowiak, Antoni Staniewski, Zofia Szymańska, Barbara Zalewska, et al.

    Chlorogenic acid (CGA), an ester of caffeic and quinic acids, is a dietary polyphenol abundant in coffee, tea, fruits, vegetables, and medicinal plants, with 5-O-caffeoylquinic acid (5-CQA) as its predominant isomer. This review aims to summarize current knowledge on the biological activities, mechanisms of action, and potential therapeutic applications of CGA in the prevention and management of metabolic disorders. CGA demonstrates a broad spectrum of biological activities relevant to human health. Its mechanisms of action involve modulation of oxidative stress and key cellular signaling pathways, as well as regulation of metabolic processes, contributing to improved insulin sensitivity, lipid balance, and overall energy homeostasis. These properties make CGA a promising agent against metabolic syndrome (type 2 diabetes, obesity, hypertension, and dyslipidemia) which is a major global health challenge. Despite its health benefits, CGA’s oral bioavailability remains limited, prompting research into optimized extraction methods, novel formulations, and structural modifications. Current evidence supports its safety even at high doses, reinforcing its potential as a nutraceutical, functional food ingredient, and adjunctive therapeutic compound in chronic disease management.